{"id":"NCT03769090","sponsor":"Bond Avillion 2 Development LP","briefTitle":"A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma","officialTitle":"A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-13","primaryCompletion":"2021-08-19","completion":"2022-02-07","firstPosted":"2018-12-07","resultsPosted":"2022-09-28","lastUpdate":"2022-09-28"},"enrollment":3132,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg","otherNames":[]},{"type":"DRUG","name":"Albuterol sulfate metered-dose inhaler 180 μg","otherNames":[]}],"arms":[{"label":"BDA MDI (PT027) 160/180 μg","type":"EXPERIMENTAL"},{"label":"BDA MDI (PT027) 80/180 μg","type":"EXPERIMENTAL"},{"label":"AS MDI (PT007) 180 µg","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.","primaryOutcome":{"measure":"Number of Participants With a Severe Asthma Exacerbation Event","timeFrame":"From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.","effectByArm":[{"arm":"BDA MDI 160/180 μg (Full Analysis Set; >=12 Years)","deltaMin":207,"sd":null},{"arm":"AS MDI 180 μg (Full Analysis Set; >=12 Years)","deltaMin":266,"sd":null},{"arm":"BDA MDI 80/180 μg (Full Analysis Set)","deltaMin":241,"sd":null},{"arm":"AS MDI 180 μg (Full Analysis Set)","deltaMin":276,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG002 vs OG003","p":"0.041"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":345,"countries":["United States","Argentina","Canada","Czechia","Germany","Serbia","Slovakia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["34887317","35569035","40664332","36161875"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":1015},"commonTop":["Nasopharyngitis","Headache","COVID-19","Upper respiratory tract infection","Bronchitis"]}}